•Overview of current approach to drug claims in psychopharmacology
•Current regulatory approach to schizophrenia
•Pseudospecificity: Regulatory basis for critical examination of proposal to focus on cognitive deficits
in schizophrenia as a
distinct target
•Criteria for establishing cognitive deficits in
schizophrenia as a unique
aspect of this illness for drug development
•Practical issues in implementing a development program for cognitive deficits in schizophrenia